Search

An effective vaccine against the Plasmodium parasite is likely to require the induction of robust antibody and T cell responses. Chimeric virus-like particles are an effective vaccine platform for induction of antibody responses, but their capacity to induce robust cellular responses and cell-mediated protection against pathogen challenge has not been established. To evaluate this, we produced chimeric constructs using the murine polyomavirus structural protein with surface-exposed CD8+ or CD4+ T cell or B cell repeat epitopes derived from the Plasmodium yoelii circumsporozoite protein, and assessed immunogenicity and protective capacity in a murine model. Robust CD8+ T cell responses were induced by immunization with the chimeric CD8+ T cell epitope virus-like particles, however CD4+ T cell responses were very low. The B cell chimeric construct induced robust antibody responses but there was no apparent synergy when T cell and B cell constructs were administered as a pool. A heterologous prime/boost regimen using plasmid DNA priming followed by a VLP boost was more effective than homologous VLP immunization for cellular immunity and protection. These data show that chimeric murine polyomavirus virus-like particles are a good platform for induction of CD8+ T cell responses as well as antibody responses. [ABSTRACT FROM AUTHOR]

Highlights: [•] Silica nanoparticles were used to adjuvant sub-unit protein antigen. [•] Nanoparticles boosted antigen immune response without protein conjugation. [•] Non-carrier nanoparticles adjuvanting efficacy depends on particle size. [ABSTRACT FROM AUTHOR]

ABSTRACT Effective and low-cost vaccines are essential to control severe group A streptococcus (GAS) infections prevalent in low-income nations and the Australian aboriginal communities. Highly diverse and endemic circulating GAS strains mandate broad-coverage and customized vaccines. This study describes an approach to deliver cross-reactive antigens from endemic GAS strains using modular virus-like particle (VLP) and capsomere systems. The antigens studied were three heterologous N-terminal peptides (GAS1, GAS2, and GAS3) from the GAS surface M-protein that are specific to endemic strains in Australia Northern Territory Aboriginal communities. In vivo data presented here demonstrated salient characteristics of the modular delivery systems in the context of GAS vaccine design. First, the antigenic peptides, when delivered by unadjuvanted modular VLPs or adjuvanted capsomeres, induced high titers of peptide-specific IgG antibodies (over 1 × 104). Second, delivery by capsomere was superior to VLP for one of the peptides investigated (GAS3), demonstrating that the delivery system relative effectiveness was antigen-dependant. Third, significant cross-reactivity of GAS2-induced IgG with GAS1 was observed using either VLP or capsomere, showing the possibility of broad-coverage vaccine design using these delivery systems and cross-reactive antigens. Fourth, a formulation containing three pre-mixed modular VLPs, each at a low dose of 5 μg (corresponding to <600 ng of each GAS peptide), induced significant titers of IgGs specific to each peptide, demonstrating that a multivalent, broad-coverage VLP vaccine formulation was possible. In summary, the modular VLPs and capsomeres reported here demonstrate, with promising preliminary data, innovative ways to design GAS vaccines using VLP and capsomere delivery systems amenable to microbial synthesis, potentially adoptable by developing countries. Biotechnol. Bioeng. 2014;111: 1062-1070. © 2013 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]

Abstract: Faster and cheaper vaccine manufacture based on modern technologies is increasingly needed to effectively mitigate the burden of disease caused by highly contagious and mutagenic pathogens, such as influenza viruses. This study describes an approach to synthetically engineer a new influenza vaccine system by antigenic modularization of a carrier viral capsomere, coupled with microbial processing of the sub-unit vaccine. This approach leads to a system optimized with respect to both biological and process criteria. Murine polyomavirus VP1 protein, which self assembles into a pentameric sub-unit capsomere of a virus-like particle (VLP), was engineered to inhibit VLP assembly and to allow modular insertion of influenza M2e antigen at multiple sites within the protein. The yield, solubility, and immunogenicity of the resulting modular capsomeres could be optimized by varying the module insertion site and the number of M2e modules per site. This study demonstrated, for the first time, an innovative strategy of inserting multiple antigenic modules, up to 45 M2e modules, in a single capsomere. Modularization of M2e antigen was shown to improve its immunogenicity by more than an order of magnitude over that attained by immunization with an equivalent mass of non-modularized M2e peptide. Vaccination of mice using modular capsomeres induced high antigen-specific antibody levels suggestive of protective efficacy. This modular vaccine design approach, inspired by synthetic biology approaches to new system development, is conducive to technologies rapidly adaptable to pathogenic variations. [Copyright &y& Elsevier]

ABSTRACT Modularization of a peptide antigen for presentation on a microbially synthesized murine polyomavirus (MuPyV) virus-like particle (VLP) offers a new alternative for rapid and low-cost vaccine delivery at a global scale. In this approach, heterologous modules containing peptide antigenic elements are fused to and displayed on the VLP carrier, allowing enhancement of peptide immunogenicity via ordered and densely repeated presentation of the modules. This study addresses two key engineering questions pertaining to this platform, exploring the effects of (i) pre-existing carrier-specific immunity on modular VLP vaccine effectiveness and (ii) increase in the antigenic element number per VLP on peptide-specific immune response. These effects were studied in a mouse model and with modular MuPyV VLPs presenting a group A streptococcus (GAS) peptide antigen, J8i. The data presented here demonstrate that immunization with a modular VLP could induce high levels of J8i-specific antibodies despite a strong pre-existing anti-carrier immune response. Doubling of the J8i antigenic element number per VLP did not enhance J8i immunogenicity at a constant peptide dose. However, the strategy, when used in conjunction with increased VLP dose, could effectively increase the peptide dose up to 10-fold, leading to a significantly higher J8i-specific antibody titer. This study further supports feasibility of the MuPyV modular VLP vaccine platform by showing that, in the absence of adjuvant, modularized GAS antigenic peptide at a dose as low as 150 ng was sufficient to raise a high level of peptide-specific IgGs indicative of bactericidal activity. Biotechnol. Bioeng. 2013; 110:2343-2351. © 2013 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]

Highlights: [•] High-throughput screening for VLP formulation combining DLS plate reader and AF4. [•] 28 formulations screened in duplicate at four temperatures using 150μg VLP. [•] Optimal formulations stabilized VLPs at elevated temperatures up to 58°C. [•] Sorbitol and Tween increased freeze–thawing (7×) and -drying recoveries (2.5×). [•] Modular VLP for GAS further stabilized by best formulation identified with wt VLP. [ABSTRACT FROM AUTHOR]

Highlights: [•] Helix 190 (H190) from influenza virus modularized onto unrelated polyomavirus VLP. [•] Antigen module design affected response quality (level of binding to HA1). [•] Flanking H190 element with GCN4 gave a low-quality response (low HA1 binding). [•] Modularizing multiple tandem repeats of H190 gave a high-quality antibody response. [•] Biomolecular engineering offers a future alternative to whole pathogen vaccines. [ABSTRACT FROM AUTHOR]